For WHO 2016 classification of gliomas the diagnostic biomarkers include IDH mutations, 1p/19q codeletion, histone-H3-encoding genes H3F3A or HIST1H3B/C K27M (H3-K27M) mutations. This evidence concerns the gene IDH1 and central nervous system cancer.